MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$99,313K
Net Income
-$47,315K
Net Profit Margin
-47.64%
EPS
-$0.11
Unit: Thousand (K) dollars
Revenue Breakdown
Revenue From Contract With Custo...
Revenue Breakdown
Gross revenue
Wholesaler fees and cash discoun...
Other rebates, returns, discount...
Government rebates and chargebac...
Revenue Breakdown
Amtagvi
Proleukin
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
99,313
71,430
86,771
67,455
Cost of sales
43,595
42,498
28,302
38,477
Research and development
58,851
62,487
68,854
75,174
Selling, general, and administrative
39,272
38,949
36,143
34,555
Depreciation and amortization
9,500
8,539
8,918*
9,007
Restructuring charges
-
-
18,014*
5,143
Total costs and expenses
151,218
152,473
160,231
162,356
Loss from operations
-51,905
-81,043
-73,460
-94,901
Interest and other income, net
3,217
1,333
1,740
1,243
Net loss before income taxes
-48,688
-79,710
-71,720
-93,658
Income tax benefit (expense)
-1,373
-665
184
-2,405
Net loss
-47,315
-79,045
-71,904
-91,253
Basic EPS
-0.11
-0.19
-176.251
-0.25
Diluted EPS
-0.11
-0.19
-173.406
-
Basic Average Shares
450,189
418,511
407,964
364,037
Diluted Average Shares
450,189
418,511
414,656
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Net loss
-$47,315K
(57.63%↑ Y/Y)
Income tax benefit
(expense)
-$1,373K
(-169.06%↓ Y/Y)
Revenue From Contract
With Customer Gross
$100,663K
(85.35%↑ Y/Y)
Net loss before
income taxes
-$48,688K
(55.60%↑ Y/Y)
Interest and other
income, net
$3,217K
(-21.61%↓ Y/Y)
Amount, before
adjustments, of revenue from...
$100,663K
(65.38%↑ Y/Y)
Loss from operations
-$51,905K
(54.38%↑ Y/Y)
Total revenue
$99,313K
(65.65%↑ Y/Y)
Amount of adjustments
from gross revenues...
-$1,350K
(-47.70%↓ Y/Y)
Total costs and
expenses
$151,218K
(-12.96%↓ Y/Y)
Research and development
$58,851K
(-25.85%↓ Y/Y)
Cost of sales
$43,595K
(-23.06%↓ Y/Y)
Selling, general, and
administrative
$39,272K
(4.17%↑ Y/Y)
Depreciation and
amortization
$9,500K
Buy us a coffee
IOVA_BIG-svg
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVA_BIG-svg
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
🚨
Price Alert:
The stock price jumped by 36.18% after the earning call.
Show more